SARS-CoV2 is known for causing atypical pneumonia with rapidly progressive respiratory failure requiring intubation. Usage of steroids have been shown to be of benefit in similar disease processes caused by other coronaviruses specifically SARS/MERS. Currently in the literature there is lack of consensus regarding steroids use in severely ill patients with COVID-19 pneumonia. We conducted a retrospective analysis to evaluate the efficacy of systemic corticosteroids and outcomes in COVID-19 patients with severe respiratory symptoms requiring ICU admission in a community hospital in Michigan. METHODS: This retrospective cohort study was conducted with 181 patients of COVID-19 with severe respiratory symptoms requiring ICU admission in a community hospital in Michigan March 18 to April 15, 2020. Patients were then divided into 2 groups, with or without steroid treatment. Treatment group received oral prednisone, doses range from 10 to 60mg twice daily for an average of 5 days, most of which received a loading dose of intravenous methylprednisolone. The primary outcome for the study was mortality rate, secondary outcome was extubation rate. RESULTS: 177 patients met inclusion criteria and among those, 93 patients received systemic steroids. Of the total 93 patients in the treatment group, 42 patients were admitted to ICU, 38 of which were intubated. Of the total 84 patients in the control group, 14 patients were admitted to ICU and 10 were intubated. The mortality rate was 53% in the treatment group compared to 57% in the control group (p>0.05); the extubation rate was 71% in the treatment group compared to 50% in the control group (p>0.05). Our results showed a clinically important difference between the two groups.
INTRODUCTION:
Angiotensin-converting enzyme inhibitors (ACEi) are generally known to cause angioedema, with the face, tongue, and pharynx primarily involved. ACEi-induced small bowel angioedema is relatively rare occurring in 0.1 to 0.7% patients on ACEi.
CASE DESCRIPTION/METHODS:
Our case report is about a 34-year-old woman who was recently started on lisinopril and diagnosed with angioedema of the stomach and duodenum. The patient presented to our hospital with a 3-week history of nausea and a 2-day history of worsening epigastric pain. She also had one episode of non-bilious emesis and one episode of watery diarrhea. Her home medications included lisinopril 20 mg daily for hypertension, which she started taking 3 weeks ago. She was hemodynamically stable and physical examination revealed mild epigastric tenderness with no organomegaly, guarding or rebound tenderness. Laboratory values were significant for leukocytosis of 12,000, and normal complement and lipase levels. Abdominal computed tomography (CT) scan showed signs of findings of acute severe enteritis involving the duodenum and proximal jejunum, with no pancreatitis. Endoscopy revealed edema of the duodenum. Given the high suspicion for ACEi induced angioedema of the small bowel, her lisinopril was discontinued and the patient showed complete symptom resolution within 24 hours.
DISCUSSION:
ACEi-induced angioedema of the small bowel is a rare clinical presentation, however, it is an important differential diagnosis to consider when a patient taking an ACEi presents with nausea and abdominal pain. It is important to highlight angioedema of the small bowel can occur at any time after a patient starts taking an ACEi. Although ACEi-induced small bowel angioedema is relatively rare, its recognition is important as ACEi use is high and misdiagnosis can lead to frequent hospital visits and unnecessary surgery. The first line treatment being discontinuation of ACEi, there are other pharmacological options including icaibant, ecallantide which have unproven efficacy from the current trails. Fresh frozen plasma has shown to have success in cases where nothing has worked. The usual dose being used to treat are 2 to 4 units of fresh frozen plasma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.